These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34882322)

  • 1. [The orphan preparations: international approaches and national regulation].
    Foteeva AV; Rostova NB; Isupova AD; Gerbergagen ES
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Nov; 29(6):1490-1497. PubMed ID: 34882322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The characteristics of restrictive listings of medications: the position of orphan medical preparations].
    Komarov IA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Dec; 30(6):1328-1330. PubMed ID: 36541317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The rare diseases and orphan medications: Placement in health care of the Russian Federation].
    Komarov IA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Jan; 31(1):16-19. PubMed ID: 36801869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of patient access to orphan drugs in Turkey.
    Koçkaya G; Atalay S; Oğuzhan G; Kurnaz M; Ökçün S; Sar Gedik Ç; Şaylan M; Şencan N
    Orphanet J Rare Dis; 2021 Feb; 16(1):68. PubMed ID: 33549137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The analysis of detection of rare diseases not included into listings of orphan diseases with preferential medication support].
    Komarov IA; Krasilnikova EI; Zhulev IA; Zinchenko RF
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2020 Sep; 28(5):893-902. PubMed ID: 33161658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
    Micallef J; Blin O
    Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
    Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
    BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in orphan medicinal products approvals in the European Union between 2010-2022.
    Bouwman L; Sepodes B; Leufkens H; Torre C
    Orphanet J Rare Dis; 2024 Feb; 19(1):91. PubMed ID: 38413985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pharmacy tourism. Part I. The analysis of state of medicinal support of patients with rare diseases].
    Ananchenkova PI; Tonkonog VV; Timchenko TN
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Jan; 31(1):33-43. PubMed ID: 36801872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drugs for rare diseases: is it time to revisit their special market access status?
    Simoens S; Cassiman D; Dooms M; Picavet E
    Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.